HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Finds Data Scarce Where US FDA Wants To Gauge Hemp Safety – Reproductive Toxicity

Executive Summary

First systematic mapping study of safety concerns for consumer use of cannabidiol identifies knowledge gaps for reproductive and developmental toxicity. No traditional, guideline-compliant developmental and reproductive toxicity study was available in the public domain through December 2020.

You may also be interested in...



Safety Concerns Are US FDA's Answer To Question On Regulatory Pathway For Hemp’s Lawful Use

While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.

Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far

FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.

Canadian Firm Aims To Cast Wide Net To Grow Using Marine Algae Phytoplankton In Nutrition

Marine algae phytoplankton is abundant with numerous vitamins and minerals and is found on the ocean’s surface. Blugenics Innovations markets Karen brand powder and tablet line with proprietary phytoplankton ingredient it also provides to other firms.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel